PBA
SRPT icon

Paradigm Biocapital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Paradigm Biocapital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-947,574
Closed -$150M – 39
2024
Q2 		$150M Sell
947,574
-130,772
-12% -$16.8M 5.73% 5
2024
Q1 		$140M Buy
+1,078,346
New +$132M 4.91% 6

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paradigm Biocapital Advisors's SRPT Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 947,574 shares — an estimated $150M sold.

Paradigm Biocapital Advisors first reported a position in SRPT in Q1 2024 and held it in 2 quarters. The position peaked at $150M in Q2 2024. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Paradigm Biocapital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 947,574 Sarepta Therapeutics shares in Q3 2024, an estimated $150M.
  • Paradigm Biocapital Advisors first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Sarepta Therapeutics position peaked at $150M in Q2 2024.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.